Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2025 Jul 29;15:27590. doi: 10.1038/s41598-025-11770-9

Retraction Note: Tiliroside as a CAXII inhibitor suppresses liver cancer development and modulates E2Fs/Caspase-3 axis

Rui Han 1,2,, Hongxing Yang 1, Lingeng Lu 3, Lizhu Lin 1,
PMCID: PMC12307769  PMID: 40730839

Retraction of: Scientific Reports 10.1038/s41598-021-88133-7, published online 21 April 2021

The Editors have retracted this Article. After publication irregularities have been identified in the presented figures, specifically:

  • In Figure 2A the 0h Hep3B Tiliroside and NC images overlap;

  • Images in Figures 3A and B overlap with images in previously published articles [1, 2].

The Authors provided data files to address these concerns; however, the Editors were unable to validate these files as original data. The Editors therefore no longer have confidence in the reliability of the results presented in this Article.

Hongxing Yang and Lingeng Lu have not responded to correspondence from the Editors about this retraction. Rui Han and Lizhu Lin have not explicitly stated if they agree or disagree with this retraction.

Contributor Information

Rui Han, Email: dianxiqiao@foxmail.com.

Lizhu Lin, Email: linlizhu@139.com.

References

  • 1.Han, R. et al. MicroRNA-34a suppresses aggressiveness of hepatocellular carcinoma by modulating E2F1, E2F3, and caspase-3. Cancer Manag Res.10(11), 2963–2976. 10.2147/CMAR.S202664 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Han, R., Nusbaum, O., Chen, X. & Zhu, Y. Valeric acid suppresses liver cancer development by acting as a novel HDAC inhibitor. Mol Ther Oncolytics.29(19), 8–18. 10.1016/j.omto.2020.08.017 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES